Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York
Open Access
- 2 July 2020
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 383 (1), 85-88
- https://doi.org/10.1056/nejmc2009567
Abstract
Data on Covid-19 in patients with immune-mediated inflammatory disease who have received anticytokine biologics, other immunomodulatory therapies, or both on a long-term basis are scarce. Trials to assess the efficacy of antirheumatic therapies such as hydroxychloroquine1 and anticytokine therapies such as interleukin-6 inhibitors2 to improve outcomes in patients with Covid-19 are ongoing. The rationale for their use is that worse outcomes (i.e., hospitalization, ventilation, or death) may be related to a proinflammatory cytokine storm.3,4Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR074500, T32AR069515)
This publication has 3 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020